Jiyuan Medical Completes Second Tranche of Series A Funding to Strengthen Global Leadership in Single-Use Hysteroscopy
Recently, Jiangsu Jiyuan Medical Technology Co., Ltd. (hereinafter referred to as “Jiyuan Medical”) announced that it has completed the second tranche of its Series A financing, amounting to tens of millions of yuan, following the first tranche of its Series A round in 2023. The funds raised in this round will be primarily used for the research and development, global regulatory registration and certification, production, and market promotion of disposable electronic hysteroscopes and配套 disposable surgical instruments, thereby further expanding its competitive advantages and laying the foundation for ARMI®The brand’s market position as “No. 1 in China and a global leader.”
Jiyuan Medical, established in 2017, specializes in the R&D, manufacturing, and sales of disposable gynecological endoscopes, committed to creating a “comprehensive solution for disposable gynecological endoscopy.” Led by its disposable electronic hysteroscope, the company provides a serialized portfolio of disposable electronic hysteroscopes and matching disposable surgical instruments that meet the diagnostic and therapeutic needs of all surgical scenarios for uterine cavity diseases. Through independent innovation and optimized integration, it has built a multi-product technology platform for disposable endoscopes, establishing compliance with Grade 3A+Gynecological Endoscopy Philosophy and the “Five-in-One” Disposable Gynecological Endoscope Integrated Solution. Globally synchronized registration and certification, promoting the concept of Natural Orifice Transluminal Endoscopic Surgery (NOTES), and gradually leading the 3A standard for disposable gynecological endoscopes.+New Era.
3A+It is the endoscopic diagnosis and treatment technology concept first proposed globally by Jiyuan Medical. Jiyuan Medical has always centered its efforts on 3A in research and development, manufacturing, marketing, and medical services.+Concept Expansion. 3A+Specifically, it refers to “Anytime, Anysite, Anybody + No Cross-Infection Risk.”As of 2023, Jiyuan Medical has launched 72 models of disposable electronic hysteroscopes and over 200 models of disposable ancillary surgical instruments, preliminarily establishing a comprehensive solution for disposable electronic hysteroscopy.
ARMI®The disposable electronic hysteroscope series has obtained registration certifications in more than 10 countries and regions, including China NMPA, US FDA, and EU CE-MDR. Its sales network covers more than 30 countries and regions, such as China, Southeast Asia, the Middle East, the United States, and Europe. Jiangsu Jiyuan Medical Technology Co., Ltd. passed the ISO 13485 quality system certification in November 2021. ARMI®The series utilizes medical-grade chips and adopts a modular, semi-automated mass production process. Validated through multi-center clinical controlled studies and used by nearly 10,000 patients in over 800 hospitals worldwide, its product quality, functional performance, quality consistency, and technological advancement have reached an internationally leading level, earning consistent acclaim from thousands of physicians globally.
In July 2022, Professor Cao Zeyi, medical advisor to Jiangsu Jiyuan Medical Technology Co., Ltd. (former Vice Minister of the Ministry of Health and renowned gynecological expert), visited Jiangsu Jiyuan Medical in person and commented during his on-site inspection, “ARMI®“The Disposable Electronic Hysteroscope Series Will Trigger a Major Transformation in the Medical Field.” September 2023, ARMI®A delegation of global medical advisors, including Dr. Resad Paya Pasic (Former President of the International Society for Gynecologic Endoscopy), Dr. Adel Shervin (Former Executive Director of the International Society for Gynecologic Endoscopy), and Dr. Eddy Hartono (Current President of the International Society for Gynecologic Endoscopy), visited Jiangsu Jiyuan Medical Technology Co., Ltd. They unanimously declared, “An important medical revolution is unfolding globally by Jiyuan Medical.” During the visit, Dr. Resad Paya Pasic also provided on-site commentary on ARMI®The brand has been highly interpreted as “Advanced Medical Research Institute”.
After six years of dedicated cultivation, ARMI®Having achieved industry-leading positions in regulatory registration and market access, product quality, and market coverage, we are confidently and steadily advancing toward our market goal of being “No. 1 in China and a global leader.”
Hysteroscopy is the “gold standard” for diagnosing intrauterine lesions. Statistics show that the annual number of hysteroscopic diagnostic and therapeutic cases worldwide reaches 40 million, with China alone accounting for 12 million cases and an annual growth rate exceeding 10%. Professor Feng Limin, a renowned hysteroscopy expert in China, stated, “To address the growing demand for diagnosis and treatment of uterine cavity diseases, as well as the need for more diversified services (greater efficiency, minimal invasiveness, convenience, painlessness, and safety), it is essential to vigorously promote the concept of comprehensive hysteroscopy management.” Hysteroscopic diagnosis and treatment should be widely implemented in outpatient clinics, day-surgery units, and central operating rooms, particularly outpatient hysteroscopy that aligns with the model of “immediate consultation upon appointment and immediate treatment upon diagnosis.”
Disposable electronic hysteroscopes feature a high degree of digitalization, a slender scope body (≤5.0 mm) equipped with a 5Fr–6Fr instrument channel, and continuous irrigation capabilities. They meet the access requirements for vaginal endoscopy techniques in hysteroscopy and align with the outpatient hysteroscopy concept of “immediate consultation upon appointment and immediate treatment upon diagnosis.” By employing disposable endoscopic surgical instruments compatible with the “grasping” technique, these devices enable “five-exemption” hysteroscopic procedures (exempt from speculum, uterine sounding, cervical dilation, tenaculum grasping, and anesthesia). This approach maximizes diagnostic and therapeutic efficiency, reduces cervical injury to preserve fertility, and truly eliminates the risk of cross-infection. It is particularly suitable for patients with uterine abnormalities, those who have experienced failure with traditional reusable hysteroscopes, individuals with specific conditions, and patients without a history of sexual activity. Therefore, disposable electronic hysteroscopes are poised to become the cornerstone of global gynecological outpatient care and ambulatory surgery.
Against the backdrop of intensifying competition in the global medical device market, continuous technological innovation and acute market sensitivity are key to corporate survival and development.January 2024, ARMI®Second-Generation Disposable Electronic Hysteroscope Series, with a total of 60 specifications, has obtained NMPA registration certification.
ARMI®The second-generation model not only inherits the functional and performance advantages of the first generation but also comes at a lower cost. It is well-positioned to rapidly penetrate high-end markets in developed countries such as those in Europe and the United States, while simultaneously catering to the mid- and low-end markets in Southeast Asia, Africa, and other regions. By reducing healthcare costs for patients, it further enhances the allocation of primary healthcare resources and service capabilities. ARMI®The second-generation system adopts a high-definition resolution chip module and is equipped with a high-performance image processor, significantly enhancing data computation capabilities and signal processing performance in complex uterine cavity environments. It can effectively identify and diagnose occult lesions, thereby reducing missed diagnoses or accidental incidents.
2024, ARMI®The Disposable Electronic Hysteroscope Series has obtained regulatory approvals in over 130 countries and regions, with a sales network spanning more than 90 countries, solidifying its market position as “No. 1 in China and a Global Leader,” and pioneering the 3A standard in global hysteroscopic diagnosis and treatment.+In the new era, benefiting tens of millions of patients with intrauterine diseases worldwide.
Regarding this financing round,Zhang Yunfei, Chairman of Jiyuan MedicalIt indicates that the disposable endoscope industry boasts significant global market potential, with Chinese and foreign companies starting from the same baseline. In the field of gynecology, Jiyuan Medical has even taken a global lead, competing on par with worldwide industry leaders. We sincerely appreciate all investors for their recognition of the company, which has injected strong strategic momentum into the cause of human health. With the robust support of both new and existing shareholders, we will fully leverage our advantages in product technology R&D, continuously deepen our capture and understanding of clinical needs, and comprehensively enhance our ability to translate these needs into products and solutions throughout the design and production processes. On the market front, the company will strive to accelerate global commercial promotion, particularly in high-end markets such as Greater China, Europe, and the United States, providing valuable products and services to more doctors and patients, and delivering satisfactory results to shareholders within three years.